[Long term study on the efficacy and safety of lornoxicam in rheumatoid arthritis].
BACKGROUND
To assess the long term safety and therapeutic action of lornoxicam, a new non steroidal anti-inflammatory agent, in rheumatoid arthritis.


METHODS
Open trial was carried out on different dosage schedules of lornoxicam (4 or 8 mg bid and 4mg tid) administered for six to twelve months. Patients of both sexes were enrolled, with classical or definite rheumatoid arthritis according to the A.R.A. criteria.


RESULTS
Thirty-four patients (28 F, 6 M) were admitted, mean age (+/- SD) 53.9+/-14.2 years, mean duration of illness 9.2+/-10.7 years. Lornoxicam 8-16 mg/day showed good safety and therapeutic activity in long term treatment. Clinical improvement was limited, but progression of the disease was controlled. No adverse events were complained.


CONCLUSIONS
Lornoxicam presented a worth-while therapeutic action and a good tolerability in rheumatoid arthritis long term treatment.
Unità Operativa di Reumatologia, Ospedale Maggiore, Bologna, Italy.
L
L
Frizziero
M C
MC
Focherini
M
M
Valentini
M
M
Reta
P
P
Rocchi
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010894:Piroxicam / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; C059451:lornoxicam